Fair market value for anesthesia subsidies: when you need an opinion

A new anesthesia subsidy is on your desk, or an existing one is going up, and someone on your board or in compliance asks the question first: is this fair market value? It sounds like a number problem. It is really two separate legal questions, and a hospital that treats them as one tends to get an answer that satisfies no one.

This is general information about how fair market value and commercial reasonableness work in anesthesia coverage arrangements, not legal advice. The specific facts of your arrangement, and whether an independent opinion is needed, are questions for your healthcare counsel.

Why does a subsidy to a physician group raise Stark and Anti-Kickback questions at all?

A hospital and an anesthesia group have an ongoing financial relationship, and the group's physicians order hospital services such as lab tests, imaging and blood products in the course of their work. A payment from a hospital to physicians who can generate hospital business is the kind of relationship the physician self-referral law (the Stark Law) and the federal Anti-Kickback Statute are written to examine. Our open-book subsidy guide already covers the specific Stark compensation exceptions that apply to a subsidy, including the requirement that the payment formula be set in advance under 42 CFR 411.354, so we will not repeat that ground here.

The Anti-Kickback Statute is a separate law with its own exposure. It makes it a felony to knowingly and willfully offer or pay any remuneration to induce a referral of anything reimbursable under a federal health care program.¹ A subsidy is remuneration. If a court or investigator could conclude that part of the payment exists to reward or induce referrals, instead of compensating for a coverage burden the hospital actually needs covered, the arrangement is exposed under this statute regardless of how the Stark analysis comes out. A commonly used safe harbor for personal services arrangements requires that the compensation methodology be set in advance, consistent with fair market value, and not determined in a way that accounts for the volume or value of referrals.² Falling outside a safe harbor does not make an arrangement illegal, but it removes the shelter of automatic protection.

The Office of Inspector General has told hospitals for two decades what it looks for here. Its 2005 supplemental guidance for hospitals put the standard plainly: "any remuneration flowing between hospitals and physicians should be at fair market value for actual and necessary items furnished or services rendered based upon an arm's-length transaction."³ Its 2023 general compliance guidance asks the same question in updated form and adds a documentation expectation: is the remuneration fair market value in an arm's-length transaction for legitimate, reasonable and necessary services, based on a methodology that is uniformly applied and properly documented.⁴ That documentation instruction is the practical reason opinions exist. An assessment made informally, and never written down, cannot later be shown to a regulator, a plaintiff's lawyer or an incoming CFO.

What do "fair market value" and "commercially reasonable" actually mean in the regulations?

Both terms have specific definitions at 42 CFR 411.351, revised in a 2020 CMS final rule that took effect in January 2021.⁵ Fair market value is "the value in an arm's-length transaction, consistent with the general market value of the subject transaction." Commercially reasonable means the arrangement "furthers a legitimate business purpose of the parties" and "is sensible, considering the characteristics of the parties, including their size, type, scope, and specialty." The regulation adds that an arrangement can be commercially reasonable even if it does not turn a profit for one of the parties, which matters for anesthesia coverage, where hospitals routinely subsidize a service line that will never collect enough to break even on its own.

Before that 2020 rule, hospitals and their advisors often treated fair market value and commercial reasonableness as one combined test: if the price was reasonable, the arrangement itself was assumed to make sense. CMS said this had become a real source of confusion and rewrote the rule to separate them. As one law firm's client alert on the final rule summarized, the "cornerstones" of the Stark exceptions, including fair market value and commercial reasonableness, "are separate and distinct requirements that each must be satisfied."⁶ For a subsidy, that means two independent questions: is the dollar figure within a defensible market range, and does the arrangement itself make sense given what the hospital actually needs covered, its case volume, its coverage grid and its alternatives. A number can be inside a fair market value range and still fail the second test, if, for instance, the hospital is paying for call coverage at three sites when it operates two.

What does an independent opinion for an anesthesia coverage arrangement actually examine?

A useful opinion is not a single number pulled from a survey. Anesthesia-specific fair market value work generally works through the same handful of inputs, whatever firm performs it.

What it examines	Why it matters for anesthesia
Coverage requirements and call burden	After-hours, weekend and obstetric call is a real obligation on clinicians even when it produces little collectible activity, and it has to be priced as coverage, not as case volume.7
Staffing model and care-team ratios	The mix of physician anesthesiologists, certified registered nurse anesthetists (CRNAs) and certified anesthesiologist assistants (CAAs), and how Medicare splits payment under a medical direction model, drives most of the cost side. Our care-team ratios explainer covers how that math works.
Collections and revenue cycle	Net collections by payer, denial rates and days in accounts receivable, checked against the group's own billing performance and not simply accepted as given. Our pieces on anesthesia-specific billing and billing questions for hospitals go into what this data should show.
Market compensation data	Published clinician compensation and production surveys, used to bound a range instead of producing a single figure.

Two methods usually get compared: a cost approach, which starts from the documented cost of staffing the agreed coverage and subtracts expected collections, and a market approach, which benchmarks total compensation and productivity against published survey data.⁷ Where a valuation professional signs a formal conclusion of value, the AICPA's Statement on Standards for Valuation Services sets baseline expectations for how that engagement should be documented, going back to 2007.⁸ The output that matters to a hospital board is not a single dollar figure. It is a range, built from stated assumptions the hospital can check against its own coverage grid, case volume and payer mix, the same inputs our subsidy benchmarking guide recommends tracking on an ongoing basis.

When do hospitals typically get one?

There is no bright-line rule that says every subsidy needs a formal written opinion every year. This is a judgment counsel makes, weighing factors like these:

• A brand-new arrangement, where no history exists yet to show the payment tracks the hospital's actual need for coverage.
• A material increase over the prior term, where the size of the jump makes it harder to explain later without a contemporaneous record of why.
• A change in structure, such as moving from a flat stipend to the rolling, reconciled model in our open-book subsidy guide, which changes what needs to be justified and how.
• A change in the underlying facts: new sites, a different care-team ratio, a shift toward more Medicare volume or heavier locum use, all of which move the cost side of the analysis.
• Related-party or unusual terms, where anything that looks less like an arm's-length deal on its face invites more scrutiny.

No single item on that list triggers an opinion automatically. Each is an input to a decision counsel makes about the level of documentation an arrangement needs, given its size and its risk profile. Our anesthesia subsidy review work, done independently of any anesthesia group, staffing firm or vendor, is one way hospitals build that documentation before counsel is asked to sign off on it.

What are the common pitfalls that undermine an opinion?

Some patterns turn an opinion from protection into a liability.

• An opinion bought to fit a number. A hospital that already knows what figure it wants, and shops until an advisor delivers it, has not built a defense. It has built a record of shopping. The Fourth Circuit's decision against Tuomey Healthcare System, a case about part-time employment of specialists rather than anesthesia, described this pattern: the hospital's counsel worked to steer one consultant toward a favorable conclusion, terminated a second consultant's engagement after he raised concerns about the arrangement, and relied on a third opinion that never reviewed the earlier, unfavorable one.⁹ The jury found the resulting compensation arrangements did not qualify for a Stark exception, and the case ended in a $72.4 million settlement of a judgment of more than $237 million.¹⁰
• A stale opinion. An analysis performed for a prior term, or before a material change in coverage or care-team mix, does not travel forward automatically. It supported a different set of facts.
• An opinion built only on the group's own assumptions. If the coverage hours, case volume or collections in the analysis come solely from the group's model, with no check against the hospital's own OR and registration data, the opinion is only as good as an assumption the hospital never tested.
• Treating the top of the range as the default. A fair market value analysis produces a range for a reason: reasonable methods and reasonable data sources will not converge on one number. When a negotiator cites "the market rate" as a single figure, ask whose range it comes from and where in that range it sits.

Is fair market value a target to negotiate toward?

No. Fair market value sets a range. It does not set a price. A figure outside the range is a compliance problem to take to counsel; a figure inside it still has to be negotiated. Where a hospital lands inside the range is a negotiation, informed by its own coverage needs, its budget and the group's actual performance, not a figure an appraiser hands down. Our guide to reviewing a subsidy increase request walks through how to build that negotiating position from the hospital's own data once the compliance range is established.

Who performs the analysis matters here too. An opinion commissioned by the anesthesia group, or by an advisor who also helps groups negotiate against hospitals, carries a different kind of scrutiny than one a hospital commissions independently. Our guide to choosing an anesthesia consultant covers the conflicts of interest to ask about before you engage anyone to produce this kind of opinion, whether for a subsidy review, a renewal or a proposed change in structure.

Sources

1. U.S. Code, "42 U.S.C. § 1320a-7b – Criminal penalties for acts involving Federal health care programs," via Legal Information Institute, Cornell Law School, current text. https://www.law.cornell.edu/uscode/text/42/1320a-7b ↩

2. U.S. Code of Federal Regulations, "42 CFR § 1001.952 – Exceptions," via Legal Information Institute, Cornell Law School, current text. https://www.law.cornell.edu/cfr/text/42/1001.952 ↩

3. Office of Inspector General, U.S. Department of Health and Human Services, "OIG Supplemental Compliance Program Guidance for Hospitals," Federal Register, January 2005. https://oig.hhs.gov/documents/compliance-guidance/10717/notice-final-supplemental-compliance-program-guidance-for-hospitals.pdf ↩

4. Office of Inspector General, U.S. Department of Health and Human Services, "General Compliance Program Guidance," HHS-OIG, November 2023. https://oig.hhs.gov/documents/compliance-guidance/1135/HHS-OIG-GCPG-2023.pdf ↩

5. U.S. Code of Federal Regulations, "42 CFR § 411.351 – Definitions," via Legal Information Institute, Cornell Law School, current text. https://www.law.cornell.edu/cfr/text/42/411.351 ↩

6. Arnold & Porter, "HHS Finalizes New Protections Under the Stark Law for Value-Based Arrangements and Makes Other Critical Revisions and Clarifications to the Regulations that Physicians and Designated Health Service Entities Must Understand," Arnold & Porter Advisories, November 2020. https://www.arnoldporter.com/en/perspectives/advisories/2020/11/hhs-finalizes-new-protections-under-the-stark-law ↩

7. Neal D. Barker, "Anesthesia Subsidy Assessment: Fair Market Value and Beyond," American Health Law Association, April 2020. https://www.americanhealthlaw.org/getmedia/9b76ca30-b406-433c-8eea-f3720ab70416/20_HCT_ResourceGuide_HSG_Anesthesia_Subsidy_Assessment_Fair_Market_Value_and_Beyond.pdf ↩ ↩²

8. American Institute of Certified Public Accountants, "Statement on Standards for Valuation Services (VS Section 100)," AICPA & CIMA, June 2007. https://www.aicpa-cima.com/resources/download/statement-on-standards-for-valuation-services-vs-section-100 ↩

9. United States Court of Appeals for the Fourth Circuit, United States ex rel. Drakeford v. Tuomey, 792 F.3d 364, decided July 2, 2015. https://www.ca4.uscourts.gov/Opinions/Published/132219.P.pdf ↩

10. U.S. Department of Justice, Office of Public Affairs, "United States Resolves $237 Million False Claims Act Judgment against South Carolina Hospital that Made Illegal Payments to Referring Physicians," press release, October 2015. https://www.justice.gov/opa/pr/united-states-resolves-237-million-false-claims-act-judgment-against-south-carolina-hospital ↩